All In Biotech

Drug Trial Radar · NCT04940039

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

Clinical Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

93

Actual

Start

Jul 22, 2021

Primary completion

Apr 16, 2024

Study completion Apr 16, 2024

Sponsor

Lead sponsor
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 34 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the long-term symptomatic response (Visit 2 \[Week 1\] to Visit 14/Week 66 \[End of Study {EOS}\]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings with the antipsychotic regimen that starts with oral anti-psychotic (AP) formulation followed by continued treatment with (paliperidone palmitate 1-month \[PP1M\] and 3-month \[PP3M\] formulations).

Conditions

  • Schizophrenia

Interventions

  • Risperidone 3 mgDrug

    Participants will receive 3 mg oral risperidone tablet once daily for 3 days.

  • Paliperidone Palmitate 50 mg eq.Drug

    Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).

  • Paliperidone Palmitate 75 mg eq.Drug

    Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.

  • Paliperidone Palmitate 100 mg eq.Drug

    Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.

  • Paliperidone Palmitate 150 mg eq.Drug

    Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.

  • Paliperidone Palmitate 175 mg eq.Drug

    Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.

  • Paliperidone Palmitate 263 mg eq.Drug

    Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.

  • Paliperidone Palmitate 350 mg eq.Drug

    Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.

  • Paliperidone Palmitate 525 mg eq.Drug

    Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}])Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University Teaching Hospital of Butare(CHUB)

    Butare, Rwanda

  • Kibuye Referral Hospital

    Kibuye, Rwanda

  • CARAES Ndera Neuro-Psychiatric Hospital

    Kigali, Rwanda

  • University Teaching Hospital of Kigali

    Kigali, Rwanda

  • Rwamagana Provincial Hospital

    Rwamagana, Rwanda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.